Mirum Pharmaceuticals (MIRM) said Thursday that its partner Takeda Pharmaceutical (TAK) has received clearance by Japan's Ministry of Health, Labour, and Welfare for Livmarli oral solution to treat cholestatic pruritus in people with Alagille syndrome and progressive familial intrahepatic cholestasis.
Mirum said the company and Takeda signed an exclusive licensing deal in September 2021 for the development and commercialization of Livmarli for rare cholestatic pediatric liver diseases in Japan.
Under the terms of the deal, Mirum is eligible to get a percentage of Takeda's annual net sales, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.